Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease - Wikidata - wikimedia - TriplyDB

Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease

Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease

http://www.wikidata.org/entity/Q34827117

about

Manganese neurotoxicity: new perspectives from behavioral, neuroimaging, and neuropathological studies in humans and non-human primates Anterior cingulate dopamine turnover and behavior change in Parkinson's disease.Resting state functional connectivity of the striatum in Parkinson's disease.Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts.Early diagnosis and therapy of Parkinson's disease: can disease progression be curbed?[18F]FDOPA positron emission tomography in manganese-exposed workers.Inventory of real world data sources in Parkinson's disease.18F-DOPA uptake parameters in glioma: effects of patients' characteristics and prior treatment history.

P2860

Q28384717-D7F5CCE1-E4DC-4852-8F42-F593FEA76B65 Q35748883-9D33CDCA-36CA-4C48-98F2-5E8B1E793382 Q36474693-48D0C5CC-68B5-4410-A055-D792ED6F9D3F Q37955871-6AC4D046-816D-4750-B074-B4734EEE581E Q38021661-34174DEE-489A-4008-90B6-534ED3D0E381 Q46943973-603BD734-665F-4B14-9B0A-C8960B286798 Q47101523-836855C9-472A-4D89-8285-82CF17614156 Q47560758-3EBE50A7-6670-44A0-995A-0A236BB76CA9

P2860

Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease

http://www.wikidata.org/entity/Q34827117

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease

@ast

Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease

@en

Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease

@nl

type

label

Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease

@ast

Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease

@en

Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease

@nl

prefLabel

Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease

@ast

Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease

@en

Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease

@nl

P1433

Q34827117-A78150E6-71AD-494C-A225-5B7D33486E90

P1476

Q34827117-A2AFDCED-C261-4539-8561-7538E4E72A9A

P2093

Q34827117-045E24B7-4297-4CDB-ABC6-931B6195FA6B

Q34827117-1282568E-793E-4D10-960C-57CF477CE1A6

Q34827117-471F19DB-AF76-4B8D-9B88-DAA035D970ED

Q34827117-77659718-FAAF-43F4-9F6C-5C3A5BC17D99

Q34827117-B93B00B0-5BA1-4E60-ABAC-5A6817FB562C

Q34827117-BAAEA289-7619-48B1-BBF7-6A11499B5A4D

Q34827117-D4C732DB-7280-492B-8B68-03F5D363C471

Q34827117-E412D3FA-089F-4843-AC96-FC98370ACAAF

P2860

Q34827117-0371FAFF-63D5-4629-9D85-1999F4D66F23

Q34827117-04946861-2AB2-46C1-8934-499286FECD1F

Q34827117-0E971D3B-3184-40B5-9237-338146AE6F7C

Q34827117-0EB656B7-2E22-4800-87A5-B629071E277F

Q34827117-1EF654E9-79CD-4C02-AD79-A5138422A3A3

Q34827117-21B92792-45B5-4537-A67B-67E02386E2E4

Q34827117-220EE866-33EF-478A-807A-4FDACCCE5C29

Q34827117-2BED1EAA-A307-4D69-ABFF-1F560F82C4C9

Q34827117-2E5BAFC4-ECE0-4880-A710-738E61666406

Q34827117-356CCC82-93E7-4D67-888A-AAFEEF0CB30D

P304

Q34827117-3DB44A86-4B46-46FC-82A5-E935DB18301B

P31

Q34827117-40D8C56D-5649-4FDF-8B6F-B51C92C0D872

P356

Q34827117-87D9B157-AEDD-499D-95CC-9BD82E5F3D13

P407

Q34827117-48C02D3B-14A6-4958-AD92-1F252AD99B2D

P433

Q34827117-118A15A7-7A64-4BDB-AFF1-179B56EB458A

P478

Q34827117-982CD198-99CD-4530-9E1E-B4FCD12BD0CA

P50

Q34827117-4D391BFF-C340-4065-B33B-416AA79A57E9

Q34827117-CD52EF0E-BE75-4668-A9CE-11FEF648E53E

Q34827117-D06FBAD2-60FF-4C7A-9420-68C5CC4E910E

Q34827117-E556480E-BB77-42DA-83EF-A1F6F4127AC5

P577

Q34827117-9E8470CD-DC71-4AC4-A733-B096F6FB200C

P5875

Q34827117-94C926CB-6375-4D33-983D-41652F38ED8D

P698

Q34827117-982B015C-5815-43F9-A8E3-1C6CA4859C3A

P921

Q34827117-6F5A49E1-54FA-4A8C-9946-74859C55AF39

Q34827117-B93961EC-37A5-4ED5-B01E-C33C7407542F

P932

Q34827117-674B38A9-B743-41A6-BAD5-5DB0844EE27E

P356

P1433

Movement Disorders

P1476

Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease

@en

P2093

Catherine L Gallagher

http://www.w3.org/2001/XMLSchema#string

Guofan Xu

http://www.w3.org/2001/XMLSchema#string

James E Holden

http://www.w3.org/2001/XMLSchema#string

Onofre DeJesus

http://www.w3.org/2001/XMLSchema#string

Robert J Nickles

http://www.w3.org/2001/XMLSchema#string

Robert Pyzalski

http://www.w3.org/2001/XMLSchema#string

Terrence R Oakes

http://www.w3.org/2001/XMLSchema#string

W Douglas Brown

http://www.w3.org/2001/XMLSchema#string

P2860

Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations

Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data

Increase in dopamine turnover occurs early in Parkinson's disease: evidence from a new modeling approach to PET 18 F-fluorodopa data.

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease

Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease.

Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation

Positron emission tomography suggests that the rate of progression of idiopathic parkinsonism is slow.

Surrogate end points in clinical trials: are we being misled?

Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.

[(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.

P304

614-620

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.23503

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

Sterling C. Johnson

Donald G McLaren

Barbara B Bendlin

P577

2011-03-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50908487

http://www.w3.org/2001/XMLSchema#string

P698

21449008

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

corpus striatum

P932

3080432

http://www.w3.org/2001/XMLSchema#string